Barbara Schmalfeldt
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients
Bachmann H, Aminossadati B, Schmalfeldt B, Burges A, Hillemanns P, Huober J, Wollschlaeger K, Sehouli J, Siffert W, Kuhlmann J, Kimmig R, du Bois A, Meier W, Wimberger P. The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients. Br J Clin Pharmacol 2015; 80:1139-48.
Jul 22, 2015The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients
Jul 22, 2015Br J Clin Pharmacol 2015; 80:1139-48
Bachmann Hagen Sjard, Aminossadati Behnaz, Schmalfeldt Barbara, Burges Alexander, Hillemanns Peter, Huober Jens, Wollschlaeger Kerstin, Sehouli Jalid, Siffert Winfried, Kuhlmann Jan Dominik, Kimmig Rainer, du Bois Andreas, Meier Werner, Wimberger Pauline
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV
Meier W, Burges A, Stähle A, Belau A, Schröder W, Richter B, Wimberger P, Schmalfeldt B, Canzler U, Kreienberg R, Wollschlaeger K, Huober J, Baumann K, Gropp-Meier M, Rau J, du Bois A, Sehouli J. Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. Gynecol Oncol 2012; 126:236-40.
May 4, 2012Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV
May 4, 2012Gynecol Oncol 2012; 126:236-40
Meier Werner, Burges Alexander, Stähle Anne, Belau Antje, Schröder Willibald, Richter Barbara, Wimberger Pauline, Schmalfeldt Barbara, Canzler Ulrich, Kreienberg Rolf, Wollschlaeger Kerstin, Huober Jens, Baumann Klaus, Gropp-Meier Martina, Rau Jörn, du Bois Andreas, Sehouli Jalid
Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Pfisterer J, Arnold N, Burchardi N, Schmalfeldt B, Huober J, Harter P, Kommoss F, Bentz E, du Bois A, Hilpert F. Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009; 19:109-15.
Jan 1, 2009Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany
Jan 1, 2009International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2009; 19:109-15
Pfisterer Jacobus, Arnold Norbert, Burchardi Nicole, Schmalfeldt Barbara, Huober Jens, Harter Philipp, Kommoss Friedrich, Bentz Eva-Katrin, du Bois Andreas, Hilpert Felix
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
Wagner U, Jackisch C, Meier W, Schmalfeldt B, Stähle A, Gropp M, Sehouli J, Lück H, Loibl S, Huober J, Pfisterer J, du Bois A, AGO Ovarian Cancer Study Group. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecologic oncology 2007; 105:132-7.
Apr 1, 2007Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)
Apr 1, 2007Gynecologic oncology 2007; 105:132-7
Wagner Uwe, Jackisch Christian, Meier Werner, Schmalfeldt Barbara, Stähle Anne, Gropp Martina, Sehouli Jalid, Lück Hans-Joachim, Loibl Sybille, Huober Jens, Pfisterer Jacobus, du Bois Andreas, AGO Ovarian Cancer Study Group
Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Harter P, Emons G, Pfisterer J, Wollschlaeger K, Meerpohl H, Breitbach G, Tanner B, Sehouli J, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee, Schmalfeldt B, Muenstedt K, Schröder W, du Bois A, Hahmann M, Hasenburg A, Burges A, Loibl S, Gropp M, Huober J, Fink D, AGO Ovarian Cancer Study Group. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Annals of surgical oncology 2006; 13:1702-10.
Dec 1, 2006Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
Dec 1, 2006Annals of surgical oncology 2006; 13:1702-10
Harter Philipp, Emons Guenter, Pfisterer Jacobus, Wollschlaeger Kerstin, Meerpohl Hans-Gerd, Breitbach Georg-Peter, Tanner Berno, Sehouli Jalid, Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Committee, Schmalfeldt Barbara, Muenstedt Karsten, Schröder Willibald, du Bois Andreas, Hahmann Maik, Hasenburg Annette, Burges Alexander, Loibl Sibylle, Gropp Martina, Huober Jens, Fink Daniel, AGO Ovarian Cancer Study Group